Acquired inhibitors against coagulation factor VIII (FVIII), also termed acquired haemophilia A, neutralize its procoagulant function and result in severe or often life-threatening bleeding. The antibodies arise in individuals with no prior history of clinical bleeding. Acquired haemophilia occurs rarely with the incidence of approximately 1 to 4 per million/year, with severe bleeds in up to 90...

REFERENCES [1] Bonnet, P., et al. „Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries.“ Haemophilia (2009): 1-7. [2] Astermark, J., et al. „A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Compar...